Alector Q2 2026: Cash Runway Extended Through 2027, Lead Alzheimer's Program AL137 Targets IND in Q1 2027
ALEC sits 63% above its 52-week low of $1.09 on elevated volume (7.2× avg).
Summary
Alector's Q2 2026 earnings show a reduced net loss and extended cash runway through 2027, while the lead Alzheimer's program AL137 advances toward an IND filing in early 2027 — a key milestone for the struggling biotech.
Key Events · Earnings and Guidance · ALEC
-
Q2 2026 Financial Results
Revenue of $3.3M, net loss of $23.0M ($0.21/share), and cash of $172.8M as of June 30, 2026. Management expects cash to fund operations at least through 2027.
-
AL137 Lead Program Advancement
AL137 selected as lead ABC-enabled anti-Aβ antibody for Alzheimer's; IND submission targeted Q1 2027 with first-in-human dosing in Australia no later than April 2027.
-
Pipeline Progress Across Modalities
AL064/AL164 tau siRNA program entering IND-enabling studies; AL050 GCase ERT shows increased brain GCase activity in preclinical models; early-stage siRNA programs ADP062-ABC and ADP065-ABC advancing.
-
Financial Position and Runway
Cash declined from $256.0M at year-end 2025 to $172.8M; stockholders' equity turned negative at -$10.0M. Extended runway provides bridge to key clinical milestones.
Analysis · ALEC · Life Sciences
Alector reported Q2 2026 results with a net loss of $23.0 million on $3.3 million in revenue, while cash of $172.8 million is now expected to fund operations at least through 2027 — a critical survival signal after the GSK collaboration termination and recent clinical failures. The pipeline update is the real story: AL137, the lead ABC-enabled anti-amyloid beta antibody for Alzheimer's, is on track for an IND submission in Q1 2027 and first-in-human dosing by April 2027, offering a tangible near-term catalyst. Progress across tau siRNA (AL064/AL164) and GCase ERT (AL050) programs reinforces the versatility of the ABC platform, but the company remains in a precarious financial position with negative stockholders' equity and a stock price near $1.78.
At the time of this filing, ALEC was trading at $1.78 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $203.2M. The 52-week trading range was $1.09 to $3.40. This filing was assessed with neutral market sentiment and an importance score of 7 out of 10.